KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2025)

Rigel Pharmaceuticals has reported Total Debt over the past 7 years, most recently at $82.1 million for Q4 2025.

  • For Q4 2025, Total Debt rose 22.63% year-over-year to $82.1 million; the TTM value through Dec 2025 reached $82.1 million, up 22.63%, while the annual FY2025 figure was $82.1 million, 22.63% up from the prior year.
  • Total Debt for Q4 2025 was $82.1 million at Rigel Pharmaceuticals, up from $59.7 million in the prior quarter.
  • Over five years, Total Debt peaked at $82.1 million in Q4 2025 and troughed at $19.8 million in Q1 2021.
  • A 5-year average of $48.2 million and a median of $59.6 million in 2023 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: surged 101.89% in 2021 and later fell 0.05% in 2025.
  • Year by year, Total Debt stood at $19.9 million in 2021, then skyrocketed by 98.09% to $39.4 million in 2022, then soared by 51.09% to $59.6 million in 2023, then grew by 12.33% to $67.0 million in 2024, then increased by 22.63% to $82.1 million in 2025.
  • Business Quant data shows Total Debt for RIGL at $82.1 million in Q4 2025, $59.7 million in Q3 2025, and $59.8 million in Q2 2025.